Conditions: GVHD; Hematopoietic Cell Transplantation (HCT); Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes; Myelofibrosis (MF); Chronic Myeloid Leukemia (CML); Chronic Myelomonocytic Leukemia (CMML)
Interventions: Drug: Tacrolimus; Other: Early Tacrolimus Taper Strategy
Sponsors: Stanford University; Eurofins Viracor Biopharma
Not yet **RECRUITING NOW**
Interventions: Drug: Tacrolimus; Other: Early Tacrolimus Taper Strategy
Sponsors: Stanford University; Eurofins Viracor Biopharma
Not yet **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
